文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu肽受体放射性核素治疗的快速安全输注方案

A Rapid and Safe Infusion Protocol for 177Lu Peptide Receptor Radionuclide Therapy.
PubMed 文献 · J Nucl Med · 2020-11-27

本研究评估177Lu标记生长抑素类似物PRRT中输注时间短于5分钟的快速输注方案的安全性。结论认为输注时间短于5分钟的快速输注在临床实践中安全可行。

要点

  • 随访期间3/4级血液学毒性发生1例(3.2%),无3/4级肾毒性。
  • 重力法模拟实验显示3.5分钟输注一半活度、15分钟内输注95%活度。

核心结论

  • 177Lu-PRRT采用短于5分钟的快速输注在临床实践中安全可行。

研究设计与样本

  • 另进行实验室实验,模拟重力法的标准输注方案。

主要发现

  • 随访期间临床毒性主要为1/2级乏力(87.1%)和1级恶心或呕吐(67.7%)。
  • 未报告可能与快速输注方案相关的急性或长期临床毒性。
  • PRRT后3/4级血液学毒性发生于1例患者(3.2%),无3/4级肾毒性发生。
  • 实验室实验显示重力法输注时3.5分钟输注一半活度,15分钟内输注95%活度。

临床怎么用

  • 可将177Lu-PRRT输注时间缩短至5分钟以内,以提升临床流程效率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peptide receptor radionuclide therapy (PRRT) with 177Lu-labeled somatostatin analogs in patients with somatostatin receptor-expressing tumors is often performed using administration protocols prescribing a 30-min infusion time. The most often used method of infusion is the gravity method, by which the complete dose is effectively administered exponentially. However, there is no evidence to explicitly support an infusion time of 30 min. This study aims to investigate the safety of an infusion time of less than 5 min. Methods: A cohort study was performed, examining the biochemical and clinical toxicity after PRRT when using a fast-infusion protocol with a maximum infusion time of 5 min. Data on patient characteristics, laboratory tests, follow-up visits, and pre- and posttreatment imaging using 68Ga-DOTATOC PET/CT from patients treated with PRRT at the University Medical Center Utrecht (UMC Utrecht) were collected. All patients receiving PRRT using the fast-infusion protocol were included. If no laboratory or clinical follow-up was available, patients were excluded. In addition, a laboratory experiment was performed, simulating the standard-infusion protocol using the gravity method. Results: Thirty-one patients, treated using the fast-infusion protocol, were included. Clinical toxicity mainly consisted of grade 1/2 fatigue (87.1%) and grade 1 nausea or vomiting (67.7%) during follow-up. No acute or long-term clinical toxicity possibly related to the fast-infusion protocol was reported. Grade 3/4 hematologic toxicity occurred after PRRT in 1 patient (3.2%). No grade 3/4 renal toxicity occurred. The laboratory experiment showed that when using the gravity method for infusion, half of the activity is infused after 3.5 min, and 95% is infused within 15 min. Conclusion: A faster infusion of PRRT using an infusion time of less than 5 min is safe and feasible in clinical practice.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ebbers SC, Barentsz MW, de Keizer B, et al. A Rapid and Safe Infusion Protocol for 177Lu Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020. PMID: 33246981. doi:10.2967/jnumed.120.252494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。